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Mutations in the genes encoding LRRK2 and a-synuclein cause autosomal dominant forms of familial
Parkinson’s disease (PD). Fibrillar forms of a-synuclein are a major component of Lewy bodies, the intracy-
toplasmic proteinaceous inclusions that are a pathological hallmark of idiopathic and certain familial forms of
PD. LRRK2 mutations cause late-onset familial PD with a clinical, neurochemical and, for the most part,
neuropathological phenotype that is indistinguishable from idiopathic PD. Importantly, a-synuclein-positive
Lewy bodies are the most common pathology identified in the brains of PD subjects harboring LRRK2 muta-
tions. These observations may suggest that LRRK2 functions in a common pathway with a-synuclein to regu-
late its aggregation. To explore the potential pathophysiological interaction between LRRK2 and a-synuclein
in vivo, we modulated LRRK2 expression in a well-established human A53T a-synuclein transgenic mouse
model with transgene expression driven by the hindbrain-selective prion protein promoter. Deletion of
LRRK2 or overexpression of human G2019S-LRRK2 has minimal impact on the lethal neurodegenerative
phenotype that develops in A53T a-synuclein transgenic mice, including premature lethality, pre-symptom-
atic behavioral deficits and human a-synuclein or glial neuropathology. We also find that endogenous
or human LRRK2 and A53T a-synuclein do not interact together to influence the number of nigrostriatal
dopaminergic neurons. Taken together, our data suggest that a-synuclein-related pathology, which occurs
predominantly in the hindbrain of this A53T a-synuclein mouse model, occurs largely independently from
LRRK2 expression. These observations fail to provide support for a pathophysiological interaction of
LRRK2 and a-synuclein in vivo, at least within neurons of the mouse hindbrain.
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INTRODUCTION
Parkinson’s disease (PD) typically occurs in a sporadic
manner, although 5–10% of cases have a familial origin
(1,2). Mutations in at least eight genes are known to cause
familial forms of PD. Of these, mutations in the a-synuclein
and LRRK2 genes cause autosomal dominant forms of familial
PD (1,2). Mutations in the LRRK2 gene (PARK8, OMIM
609007) cause late-onset familial PD with a clinical and
neurochemical phenotype that is indistinguishable from idio-
pathic PD (3–5). LRRK2 mutations represent the most
common known cause of PD (3). At least six missense muta-
tions have been identified that segregate with disease in
LRRK2-linked families, with the G2019S mutation represent-
ing the most common variant (3). The molecular basis of
LRRK2-mediated neurodegeneration is poorly understood
but may involve alterations in LRRK2-related signaling path-
ways or enzymatic activity (6–8).
Mutations in the a-synuclein gene (PARK1, OMIM 168601
and PARK4, OMIM 605543) represent a relatively rare cause
of familial PD (1). Missense mutations (A30P, E46K and
A53T) or gene multiplications cause disease in a small
number of families (9–12). Common variation in the
a-synuclein gene is associated with the risk of developing
PD (13,14). a-Synuclein protein is the primary component
of Lewy bodies, intracytoplasmic proteinaceous inclusions,
which represent the hallmark neuropathology of sporadic
and some familial forms of PD where they occur in surviving
dopaminergic neurons of the substantia nigra (15). Mutations
and increased gene dosage of a-synuclein promote its fibrilli-
zation and aggregation which is considered to underlie
a-synuclein-mediated neurodegeneration (16).
The pathological interplay between LRRK2 and
a-synuclein is poorly understood and whether they function
in a common pathway, in parallel pathways or independently
to mediate neurodegeneration in PD is not yet clear. In favor
of a common pathway is the observation that the brains of
PD subjects with LRRK2 mutations predominantly exhibit
a-synuclein-positive Lewy body pathology, suggesting that
LRRK2 could lie upstream of a-synuclein to modulate its
aggregation and toxicity (5,17,18). However, a formal proof
of such a mechanism is currently lacking since LRRK2 trans-
genic mice and viral-based rodent models generally fail to
develop a-synuclein-related pathology (19–25). Instead,
certain LRRK2 rodent models can develop tau-related path-
ology which has also been reported in brains from certain
PD subjects with LRRK2 mutations albeit occurring less com-
monly than a-synuclein pathology (5,19,21,23,26). LRRK2 is
also not a major component of Lewy bodies found in PD
brains, suggesting that it is unlikely to be required for their
formation (27–29).
In vitro studies have so far failed to demonstrate that
a-synuclein is a direct substrate for the kinase activity of
LRRK2 (30). A recent study has suggested that LRRK2 may
function to inhibit the proteasome, thereby indirectly promot-
ing the accumulation of a-synuclein and other proteasomal
substrates (31). Moreover, LRRK2 was recently shown to
regulate the progression of neuropathology induced by the ex-
pression of A53T a-synuclein selectively in mouse forebrain
neurons (22). The pathologic interaction of a-synuclein and
LRRK2 in the regions of the nervous system that exhibit
extensive pathology in PD is not known.
Here, we further explore the pathophysiological interplay
between LRRK2 and a-synuclein in vivo by modulating
LRRK2 expression in a well-established A53T a-synuclein
transgenic mouse model under the control of the hindbrain-
selective prion protein (PrP) promoter. We find that the
overexpression of human G2019S-LRRK2 or the ablation of
endogenous LRRK2 has minimal impact on the lethal neuro-
degenerative phenotype that occurs in A53T a-synuclein
transgenic mice. Our data suggest that a-synuclein-related
pathology in this mouse model occurs largely independently
from LRRK2 expression, and further suggest that key
differences may exist in the activity or function of LRRK2
between forebrain and hindbrain neurons.
RESULTS
Generation of A53T-a-Syn/LRRK2-knockout
and A53T-a-Syn/G2019S-LRRK2 mice
To examine the potential interaction ofa-synuclein and LRRK2
in vivo, mice were generated to overexpress human A53T
mutant a-synuclein (A53T-a-Syn) either on an LRRK2 null
background or with overexpression of human G2019S mutant
LRRK2 (Fig. 1). We developed appropriate crossbreeding strat-
egies of existing genetically modified mouse models. Mice in
which both alleles of the LRRK2 gene have been disrupted by
targeted deletion of exon 40 [LRRK2-knockout (KO) mice]
(32) were bred to A53T-a-Syn transgenic mice driven by the
Figure 1. Breeding strategy to generate double mutant mice. (A) Strategy to
generate A53T-a-Syn mice on an LRRK2 null background. F0, F1 and F2 rep-
resent each generation of crossbreeding. The expected frequency of each geno-
type is indicated as a percent. (B) Strategy to generate bigenic mice
co-expressing A53T-a-Syn and G2019S-LRRK2.
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mouse PrP promoter (33) in two successive breeding steps
(Fig. 1A), as described previously (34). To minimize potential
strain effects, LRRK2 heterozygous mice (LRRK2+/2) were
bred to double heterozygous mice (A53T-a-SynTg/
LRRK2+/2) generated from the first round of breeding. We gen-
erated cohorts of age-matched littermates consisting of (i) wild-
type (WT), (ii) LRRK22/2 (LRRK2KO), (iii) A53T-a-SynTg
(SynA53T) and (iv) A53T-a-SynTg/LRRK22/2 (SynA53T/
LRRK2KO) mice at expected Mendelian ratios for further ana-
lysis (Fig. 1A). Transgenic mice overexpressing human
G2019S mutant LRRK2 driven by a hybrid CMV-enhanced
platelet-derived growth factor-b chain (CMVe-PDGFb)
promoter (24) were bred to A53T-a-Syn transgenic mice.
We crossed hemizygous G2019S-LRRK2 mice (G2019S-
LRRK2Tg) with hemizygous A53T-a-Syn mice to produce
cohorts of age-matched littermates consisting of (i) WT, (ii)
G2019S-LRRK2Tg (LRRK2G2019S), (iii) A53T-a-SynTg
(SynA53T) and (iv) G2019S-LRRK2Tg/A53T-a-SynTg
(LRRK2G2019S/SynA53T) genotypes at expected ratios (Fig. 1B).
Next, mRNA expression analysis was conducted in the
individual mouse lines to assess the expression patterns of
the A53T-a-Syn and G2019S-LRRK2 transgenes, as well as
endogenous LRRK2 expression, in the brain by in situ hybrid-
ization with 33P-labeled oligonucleotide probes (Fig. 2).
Human A53T-a-Syn mRNA is expressed widely and abun-
dantly throughout the brain of 7-month-old A53T-a-Syn trans-
genic mice compared with endogenous a-Syn mRNA using
probes detecting total or mouse a-Syn (Fig. 2A). In these
same mice, endogenous LRRK2 mRNA is also widely
expressed but at comparatively lower levels and without dif-
ferences between A53T-a-Syn transgenic and non-transgenic
brains (Fig. 2A). Endogenous LRRK2 mRNA could be
detected in the striatum, cerebral cortex, hippocampus,
cerebellum and brainstem. Human G2019S-LRRK2 mRNA
is also expressed widely throughout the brain of
G2019S-LRRK2 transgenic mice, including the striatum, cere-
bral cortex, hippocampus, cerebellum and brainstem (Fig. 2B).
The brain expression pattern and the level of human
G2019S-LRRK2 or endogenous LRRK2 mRNA are similar
at 9 and 12 months, demonstrating persistent LRRK2 expres-
sion with age (Fig. 2B). Importantly, human A53T-a-Syn and
endogenous or human LRRK2 mRNAs are co-expressed
throughout the brainstem, a region that displays a significant
burden of a-Syn pathology in A53T-a-Syn transgenic mice
(35). It has not been possible to co-localize a-Syn and
LRRK2 mRNAs in brainstem neurons due to technical lim-
itations, whereas at the protein level, detection of mouse or
human LRRK2 in tissue sections has so far proven problem-
atic with currently available antibodies (data not shown).
Therefore, it is not possible to examine the co-localization
of a-Syn and LRRK2 proteins in neuronal populations of
the mouse brain using currently available reagents. Collect-
ively, we demonstrate that human A53T-a-Syn, endogenous
LRRK2 and human G2019S-LRRK2 are broadly expressed
throughout the mouse brain where they are likely to be
co-expressed in numerous anatomic regions and neuronal
populations.
Figure 2. Localization of a-Syn and LRRK2 mRNA in the brain of transgenic
mice. (A) In situ hybridization with 33P-labeled antisense oligonucleotide
probes specific to total (human + mouse) or mouse a-Syn, mouse LRRK2
or mouse TH. Autoradiographs indicate the localization of human and
mouse a-Syn, or endogenous LRRK2 and TH mRNAs in tissue sections con-
taining the striatum/cortex, hippocampus/substantia nigra (SN) and brainstem
from 7-month-old human A53T-a-Syn transgenic mice and their non-
transgenic (Non-Tg) littermate control mice. (B) Localization of human or
mouse LRRK2 mRNA in brain sections from 9- or 12-month-old human
G2019S-LRRK2 transgenic and their non-transgenic mice.
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Behavioral deficits in A53T-a-Syn transgenic mice
are not altered by deletion of LRRK2
To begin to explore the impact of LRRK2 expression on the
phenotype of A53T-a-Syn transgenic mice, we conducted be-
havioral analysis (Fig. 3). A53T-a-Syn mice normally exhibit
pre-symptomatic hyperactivity prior to disease-onset (33,34).
Accordingly, we focused on the effects of LRRK2 deletion
on the locomotor activity of A53T-a-Syn transgenic mice in
the open-field arena at 6 months of age. Both A53T-a-Syn
and A53T-a-Syn/LRRK2-KO mice exhibit a non-significant
increase in locomotor activity compared with their WT litter-
mates, but do not differ significantly from each other
(Fig. 3A). LRRK2-KO mice perform similarly to WT mice
in the open field. A53T-a-Syn mice have previously been
shown to exhibit an impaired acoustic startle response, a
measure of sensorimotor gating in the brainstem (34). There-
fore, we tested the acoustic startle response of A53T-a-Syn
mice with or without LRRK2 deletion. Both A53T-a-Syn
and A53T-a-Syn/LRRK2-KO mice display a dramatically
impaired acoustic startle response compared with their WT lit-
termates at 6 months of age (Fig. 3B). Importantly, however,
the deficits exhibited by A53T-a-Syn and A53T-a-Syn/
LRRK2-KO mice are comparable and do not significantly
differ from each other. Interestingly, LRRK2-KO mice
exhibit a modest impairment of the acoustic startle response
compared with WT mice (Fig. 3B). Similar cohorts of
A53T-a-Syn/G2019S-LRRK2 bigenic mice were not available
for behavioral analysis. Collectively, our data demonstrate
that A53T-a-Syn transgenic mice display mild hyperactivity
and a markedly impaired acoustic startle response prior to
disease-onset which is not modified by the deletion of LRRK2.
Premature lethality of A53T-a-Syn transgenic mice
is independent of LRRK2
A53T-a-Syn transgenic mice display shortened lifespan owing
to degeneration of brainstem and spinal cord neurons leading to
limb paralysis, autonomic dysfunction and premature death
(33–35). Accordingly, we assessed the impact of modulating
LRRK2 expression on the survival of A53T-a-Syn mice
(Fig. 4). A53T-a-Syn mice exhibit premature lethality ranging
from 8 to 20 months of age. However, the survival of
A53T-a-Syn/LRRK2-G2019S and A53T-a-Syn/LRRK2-KO
Figure 3. Behavioral deficits in A53T-a-Syn transgenic mice are not altered
by the absence of LRRK2. (A) In the open-field test, A53T-a-Syn mice and
A53T-a-Syn/LRRK2-KO mice display a non-significant increase in locomotor
activity compared with WT or LRRK2-KO mice at 6 months of age (n ¼ 4–7
mice/genotype). Data indicate the total number of beam breaks during the first
15 min period expressed as mean+SEM. (B) Analysis of acoustic startle
reveals markedly reduced startle in A53T-a-Syn and A53T-a-Syn/
LRRK2-KO mice, and a smaller reduction in the startle response in
LRRK2-KO mice compared with WT control mice at 6 months of age (n .
8 mice/genotype). Data indicate startle amplitude in millinewtons (mN)
expressed as mean+SEM (∗∗P , 0.001; n.s., non-significant).
Figure 4. Progression of the lethal phenotype induced by expression of human
A53T-a-Syn is independent of LRRK2. (A) The Kaplan–Meier survival
curves of A53T-a-Syn and A53T-a-Syn/G2019S-LRRK2 mice were gener-
ated by monitoring cohorts of both genotypes (a-SynA53T, n ¼ 17;
a-SynA53T/LRRK2G2019S, n ¼ 13) until mice had to be euthanized due to
the onset of terminal disease. (B) Survival curves of A53T-a-Syn
(a-SynA53T, n ¼ 11 mice) and A53T-a-Syn/LRRK2-KO (a-SynA53T/
LRRK2KO, n ¼ 21 mice) mice are also indicated.
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double mutant mice does not significantly differ from that of
single A53T-a-Syn transgenic mice (Fig. 4A and B). WT,
G2019S-LRRK2 and LRRK2-KO mice typically exhibit
normal survival up to 24 months of age (data not shown), as
reported previously (24,32). Collectively, our data reveal that
the premature death of A53T-a-Syn transgenic mice occurs in-
dependently of endogenous or pathogenic LRRK2 expression.
Modest alterations of neuropathology in A53T-a-Syn
transgenic mice by LRRK2
To further explore the effects of LRRK2 expression on the
neurodegenerative phenotype of A53T-a-Syn transgenic
mice, we assessed the extent of neuropathology in end-stage
animals. Unbiased stereology was employed to quantify
human a-Syn pathology and reactive gliosis in the brainstem
and substantia nigra pars compacta (SNpc) of 13- to
14-month-old mice at the end-stage of disease (Fig. 5). Brain-
stem and nigral tissue were subjected to immunohistochemis-
try with an antibody to phospho-S129-a-Syn, a specific
pathological form of human a-Syn. Human a-Syn pathology
was evident throughout the brainstem, including the lateral
vestibular nucleus (LVN), lateral cerebellar nucleus (LCN),
reticular formation (RF), SNpc, cerebral cortex and striatum
of A53T-a-Syn, A53T-a-Syn/LRRK2-G2019S and A53T-
a-Syn/LRRK2-KO mice but was absent from WT mice
(Fig. 5A). Quantitative stereological analysis demonstrates a
modest yet significant reduction in human a-Syn pathology
Figure 5. Abnormal accumulation of human a-Syn in the brainstem of A53T-a-Syn transgenic mice is modestly altered by modulating LRRK2 expression. (A)
Representative images of phospho-Ser129-a-Syn immunoreactivity in the LVN, LCN, RF, SNpc and cerebral cortex from 13- to 14-month-old end-stage
A53T-a-Syn, A53T-a-Syn/G2019S-LRRK2 or A53T-a-Syn/LRRK2-KO mice and their WT littermate controls. Human a-Syn pathology is absent from WT
mice, whereas mice expressing A53T-a-Syn exhibit the abnormal accumulation of phospho-Ser129-a-Syn in neuronal cell bodies and processes. Scale bar:
50 mm. (B) Stereological assessment of phospho-Ser129-a-Syn immunoreactivity in distinct brain regions from each mouse genotype (n ¼ 3 mice/genotype).
Data represent the percent area fraction of immunoreactivity expressed as mean+SEM (∗P , 0.05, ∗∗P , 0.01 or ∗∗∗P , 0.001).
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in the LCN and RF, and a non-significant reduction (P ¼
0.128) in the LVN, of A53T-a-Syn/LRRK2-KO mice com-
pared with single A53T-a-Syn mice (Fig. 5A and B).
Human a-Syn pathology is modestly increased in the RF of
A53T-a-Syn/LRRK2-G2019S mice compared with A53T-a-
Syn mice (Fig. 5A and B). Human a-Syn pathology is not dif-
ferent in the SNpc between mouse genotypes (Fig. 5B). Our
data demonstrate that LRRK2 deletion modestly and selective-
ly reduces human a-Syn pathology in the brainstem of
A53T-a-Syn transgenic mice, whereas G2019S-LRRK2
subtly enhances a-Syn pathology.
We also explored the effects of LRRK2 expression on the
level of astroglial and microglial pathology in the brainstem
and SNpc of A53T-a-Syn transgenic mice (34). Immunoreac-
tivity for the astrocytic marker, glial fibrillary acidic protein
(GFAP), was significantly increased in the RF and SNpc of
A53T-a-Syn mice compared with WT mice, whereas there is
a non-significant increase in the LVN and LCN (Fig. 6A and
B). GFAP pathology does not, however, provide a sensitive
marker to discriminate between A53T-a-Syn, A53T-a-Syn/
LRRK2-G2019S and A53T-a-Syn/LRRK2-KO mice. Similar-
ly, A53T-a-Syn mice exhibit a non-significant increase in
immunoreactivity for the microglial marker, Iba1, in the RF
but not in the LCN compared with WT mice (Fig. 7A and
B). However, Iba1 pathology in A53T-a-Syn/LRRK2-G2019S
and A53T-a-Syn/LRRK2-KO mice does not significantly
differ from A53T-a-Syn mice. Our data suggest that reactive
gliosis evident in the brainstem and substantia nigra of
A53T-a-Syn mice occurs independent of LRRK2 expression.
Modulation of LRRK2 expression in A53T-a-Syn
transgenic mice fails to influence the number
of nigrostriatal dopaminergic neurons
The expression of G2019S-LRRK2 in transgenic mice has
been shown to induce the age-dependent degeneration of
nigrostriatal dopaminergic neurons with neuronal loss occur-
ring at 20 months of age (24). We also notice that
Figure 6. Astrocytic pathology in A53T-a-Syn transgenic mice is not affected by modulating LRRK2 expression. (A) Representative images of glial fibrillary
acidic protein (GFAP) immunoreactivity in the LVN, LCN, RF and SNpc from 13- to 14-month-old end-stage A53T-a-Syn, A53T-a-Syn/G2019S-LRRK2 or
A53T-a-Syn/LRRK2-KO mice and their WT littermate controls. A normal pattern of GFAP-positive astrocytic staining is observed in WT mice, whereas mice
expressing human A53T-a-Syn reveal a marked astrocytic response in the RF and SNpc. Scale bar: 50 mm. (B) Stereological assessment of GFAP immunoreac-
tivity in distinct brain regions from each mouse genotype (n ¼ 3 mice/genotype). Data represent the percent area fraction of immunoreactivity expressed as mean+
SEM (∗P, 0.05 or ∗∗P , 0.01).
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A53T-a-Syn transgenic mice display a substantial burden of
a-Syn pathology in neurons of the SNpc (Fig. 5). To evaluate
a potential pathological interaction of A53T-a-Syn and
LRRK2 in the nigrostriatal dopaminergic pathway, we
assessed the dopaminergic neuronal number in the substantia
nigra of end-stage animals (Fig. 8). We conducted unbiased
stereological assessments of tyrosine hydroxylase
(TH)-positive and Nissl-positive dopaminergic neurons in
the SNpc to evaluate neuronal loss. In 13- to 14-month-old
end-stage mice, we do not observe dopaminergic neuronal
loss in A53T-a-Syn or G2019S-LRRK2 transgenic mice, or
LRRK2-KO mice, compared with WT littermate mice
(Fig. 8A–D). The co-expression of A53T-a-Syn and
G2019S-LRRK2 in bigenic mice does not influence the
nigral dopaminergic neuronal number compared with single
transgenic or WT mice (Fig. 8A and B). Furthermore,
A53T-a-Syn/LRRK2-KO mice display a normal complement
of dopaminergic neurons compared with control littermates
(Fig. 8C and D). These data suggest that A53T-a-Syn and
LRRK2 do not interact together to modulate the number of
nigrostriatal dopaminergic neurons.
DISCUSSION
In this study, we report the impact of modulating LRRK2
expression on the lethal neurodegenerative phenotype of
A53T-a-Syn transgenic mice. Human a-Syn and endogenous
or human LRRK2 are broadly co-expressed throughout the
mouse brain including within forebrain, midbrain and
hindbrain regions. The overexpression of human G2019S-
LRRK2 or LRRK2 deletion fails to influence the premature
lethality of A53T-a-Syn mice, whereas LRRK2 deletion has
no impact on pre-symptomatic behavioral deficits in these
mice. LRRK2 deletion modestly reduces human a-Syn path-
ology in certain brainstem nuclei of A53T-a-Syn mice,
whereas expression of G2019S-LRRK2 subtly enhances brain-
stem a-Syn pathology. However, altering LRRK2 expression
fails to modulate glial pathology in the brainstem and substan-
tia nigra of A53T-a-Syn mice. Finally, human A53T-a-Syn
and endogenous or human LRRK2 do not pathologically inter-
act together to regulate the number of nigrostriatal dopamin-
ergic neurons. Taken together, our data suggest that
neurodegenerative phenotypes that develop in PrP promoter-
driven A53T-a-Syn transgenic mice occur largely independ-
ently from LRRK2 expression.
LRRK2 expression modestly regulates human a-Syn path-
ology in select brainstem nuclei of A53T-a-Syn mice.
LRRK2 deletion reduced a-Syn pathology in the LCN and
RF, whereas G2019S-LRRK2 enhanced pathology in the RF.
The effects on a-Syn pathology are rather subtle and fail to
occur in additional brainstem nuclei or within the SNpc,
despite substantial a-Syn pathology in these regions. Further-
more, although glial pathology is evident in A53T-a-Syn
Figure 7. Microglial pathology in A53T-a-Syn transgenic mice is not affected by modulating LRRK2 expression. (A) Representative images of Iba1 immunor-
eactivity in the LCN and RF from 13- to 14-month-old end-stage A53T-a-Syn, A53T-a-Syn/G2019S-LRRK2 or A53T-a-Syn/LRRK2-KO mice and their WT
littermate controls. A normal pattern of Iba1-positive microglial staining is observed in WT mice, whereas mice expressing human A53T-a-Syn reveal a marked
microglial response in the RF but not the LCN. Scale bar: 50 mm. (B) Stereological assessment of Iba1 immunoreactivity in the LCN and RF from each mouse
genotype (n ¼ 3 mice/genotype). Data represent the percent area fraction of immunoreactivity expressed as mean+SEM. There are no statistical differences
between mouse genotypes (P . 0.05).
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mice, there is no significant influence of LRRK2 expression on
the extent of reactive gliosis. These observations may suggest
that a-Syn pathology occurs largely independently of LRRK2
expression in this A53T-a-Syn mouse model or that LRRK2 is
located downstream of a-Syn pathology where it would be
expected to have minimal impact on the development of path-
ology. However, this potential latter mechanism would not be
consistent with the occurrence of a-Syn pathology in PD
brains harboring LRRK2 mutations (5,17,18), where LRRK2
clearly lies upstream of a-Syn aggregation. Alternatively,
our findings could potentially be explained by a lack of
co-expression of human a-Syn and LRRK2 in neuronal popu-
lations that develop pathology in A53T-a-Syn mice. Current
antibodies are not useful for reliably assessing the localization
of LRRK2 in the mouse brain. Instead, in situ hybridization
analysis of endogenous and human LRRK2 mRNA revealed
a broad distribution throughout the mouse brain including
the brainstem, whereas previous studies have shown that en-
dogenous LRRK2 or human G2019S-LRRK2 are expressed
at low levels in the substantia nigra (24,36,37). Based on
these expression data, it would be expected that endogenous
and/or human LRRK2 would co-localize with human a-Syn
in a substantial number of neuronal populations in the brain-
stem and elsewhere throughout the brain.
A recent study using inducible transgenic mice demon-
strated that the specific co-expression of human
G2019S-LRRK2 and human A53T-a-Syn in CamKIIa-
positive neurons of the forebrain dramatically enhanced
a-Syn-mediated neuropathology in the striatum and cortex,
whereas ablation of LRRK2 reduced this neuropathology
(22). However, the functional significance of this altered
a-Syn pathology was not assessed at the level of motor behav-
ior or survival. In the PrP promoter-driven A53T-a-Syn mice,
hyperactivity and impaired acoustic startle that occur prior to
disease-onset were unaffected by the deletion of LRRK2.
Furthermore, the premature lethality of A53T-a-Syn mice
owing to the progressive degeneration of neuronal populations
located in the brainstem and spinal cord was not altered by
modulating LRRK2 expression. Therefore, at least in the hind-
brain where the majority of a-Syn pathology develops in the
PrP-A53T-a-Syn mice (33–35), LRRK2 expression appears
to play an insignificant role at a functional level while
subtly altering a-Syn pathology in discrete brainstem nuclei.
These observations may indicate that LRRK2 activity or
Figure 8. A53T-a-Syn and LRRK2 do not interact to influence the number of nigrostriatal dopaminergic neurons in mice. (A and C) Representative images of
TH-positive neurons in the SNpc of 13- to 14-month-old end-stage A53T-a-Syn, A53T-a-Syn/G2019S-LRRK2 and A53T-a-Syn/LRRK2-KO mice. (B and D)
Stereological assessment of the number of TH-positive and Nissl-positive dopaminergic neurons in the SNpc for each mouse genotype generated by crossbreed-
ing of (B) A53T-a-Syn and LRRK2-G2019S transgenic mice (n ¼ 3–6 mice/genotype) or (D) A53T-a-Syn and LRRK2-KO mice (n ¼ 4 mice/genotype). Data
represent the number of TH+ or Nissl+ SNpc neurons expressed as mean+SEM. There are no statistical differences between mouse genotypes (P. 0.05).
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function may be more physiologically important in forebrain
regions such as the striatum and cortex where LRRK2 is nor-
mally expressed at highest levels, compared with midbrain and
hindbrain regions where LRRK2 expression is less abundant
(28,36–40). The mechanism by which LRRK2 regulates
human a-Syn pathology in A53T-a-Syn transgenic mice in
this and previous studies (22) is unclear at present. LRRK2
could potentially impair microtubule dynamics, Golgi
complex integrity and/or the ubiquitin–proteasomal pathway
to indirectly regulate a-Syn accumulation and aggregation
(22,31). Whether LRRK2 enzymatic activity is required for
modulating a-Syn neuropathology in vivo is not yet clear
but would have important implications for the development
of disease-modifying therapies. The efficacy of LRRK2
kinase inhibitors for attenuating neurodegenerative pheno-
types in A53T-a-Syn rodent models is worthwhile evaluating
in future studies.
Collectively, our study demonstrates that LRRK2 expres-
sion plays an insignificant role in the development of neurode-
generative phenotypes occurring in A53T-a-Syn transgenic
mice under the control of the hindbrain-selective PrP pro-
moter. Future studies will aim to further clarify the patho-
physiological interaction of a-Syn and LRRK2 in the
mammalian brain and whether this interaction is of greater sig-
nificance to distinct neuronal populations such as those located
in the striatum and cortex where LRRK2 is normally most
abundant. It will also be important to oppositely explore the
role of a-Syn expression in LRRK2-mediated neurodegenera-
tion in animal models which would perhaps best recapitulate
the molecular pathway occurring in PD subjects with LRRK2
mutations and a-Syn-positive Lewy body pathology.
MATERIALS AND METHODS
Animals
Mice were housed and treated in strict accordance with the NIH
Guide for the Care and Use of Laboratory Animals. All animal
procedures were approved by the Institutional Animal Care and
Use Committees of the Johns Hopkins Medical Institutions
(Animal Welfare Assurance No. A3272-01) or were conducted
in accordance with the Swiss legislation (Canton de Vaud,
Animal Authorization No. 2293) and the European Union
directive (2010/63/EU) for the protection of animals used for
scientific purposes. Mice were maintained in a pathogen-free
barrier facility and exposed to a 12 h light/dark cycle with
food and water provided ad libitum.
Generation of double mutant mice
Transgenic mice with overexpression of human A53T-a-Syn
under the control of the mouse PrP promoter (line G2-3)
were described previously (33–35) and have been maintained
on a C57BL/6J background following at least 10 generations
of backcrossing. LRRK2-KO mice with deletion of partial
exon 39 and complete exon 40 were reported previously
(32), and subsequently maintained on a C57BL76J back-
ground. Transgenic mice with overexpression of human
G2019S-LRRK2 under the control of a CMVe-PDGFb pro-
moter (line 340) were reported previously (24) and maintained
on a C57BL76J background. Double mutant mice overexpres-
sing A53T-a-Syn in the absence of LRRK2 (A53T-a-Syn/
LRRK2-KO) and appropriate littermate controls were gener-
ated in two successive crossbreeding steps as described previ-
ously (34). Briefly, homozygous LRRK2-KO mice were
crossed with hemizygous A53T-a-Syn mice to generate
double mutant mice (A53T-a-SynTg/LRRK2+/2). These
progeny were crossed with heterozygous LRRK2+/2 mice to
produce all four genotypes for analysis. Bigenic mice were
generated by crossing hemizygous A53T-a-Syn and
G2019S-LRRK2 transgenic mice in a single crossbreeding
step. Mice were identified by genomic PCR with specific
primer pairs: G2019S-LRRK2 transgenic mice (CMVe-F1,
5′-ATTACCATGGTTCGAGGTGA-3′ and CMVe-R1, 5′-CA
AGTGTCTGCAGGAAGGTT-3′ producing a 170 bp DNA
fragment) or PrP-A53T-a-Syn mice (hSYN-S, 5′-TTCATG
AAAGGACTTTCAAAGGC-3′ and PrP-AS, 5′-GTGGATA
CCCCCTCCCCCAGCCTAGACC-3′ producing a 450 bp
DNA fragment) together with mouse glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) primers (GAPDH-F1,
5′-TGTTTGTGATGGGTGTGAAC-3′ and GAPDH-R1,
5′-TACTTGGCAGGTTTCTCCAG-3′ producing a 380 bp
DNA fragment) and LRRK2-KO mice (forward,
5′-CCCAGGGCTGAGAACGATTAAGTC-3′ and reverse,
5′-CTGGAGTGGACTCAGGGTTACAGC-3′ producing a
590 bp DNA fragment from the WT LRRK2 allele, and
primer pair forward, 5′-GGCCTACCCGCTTCCATT
GCTCAGCGG-3′ and reverse, 5′-CCGAACAAACGACCC
AACACCCGTGCG-3′ producing a 328 bp DNA fragment
from mutant LRRK2 allele).
Immunohistochemistry and histology
Immunohistochemistry was performed after intracardiac
perfusion of mice with 1× phosphate-buffered saline and 4%
paraformaldehyde (PFA). Brains were then removed, fixed
overnight in 4% PFA and cryopreserved in 30% sucrose for
48 h. Coronal sections (40 mm) from 13- to 14-month-old
animals were prepared and processed for various pathologic
markers as described previously (24,34). Tissue sections were
quenched for endogenous peroxidase activity, permeabilized
and incubated with rabbit anti-phospho-Ser129-a-synuclein
(Wako Chemicals, Richmond, VA, USA), mouse anti-GFAP
(Sigma-Aldrich, St Louis, MO, USA) or rabbit anti-Iba1
(Wako Chemicals) antibodies. Sections were processed
with biotinylated anti-rabbit or anti-mouse IgG (Jackson
ImmunoResearch, West Grove, PA, USA) and avidin–biotin
complex coupled to horseradish peroxidase (Vectastain ABC;
Vector Laboratories, Burlingame, CA, USA) and visualized
with 3,3′-diaminobenzidine (Sigma-Aldrich). Sections were
mounted, air dried, counterstained with cresyl violet,
dehydrated and coverslipped.
Stereological measurements of nigrostriatal
dopaminergic cells
Coronal midbrain sections (40 mm) from 13- to 14-month-old
end-stage symptomatic mice and their aged-matched control
littermates were processed for immunohistochemistry with
rabbit anti-TH antibody (Novus Biologicals, Littleton, CO,
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USA) and Nissl counterstain, as described previously (24,41).
Unbiased stereological methodology was employed to count
TH+ and Nissl+ neurons in the left and right SNpc region
of every fourth section throughout the ventral midbrain, as
described previously (24,41,42). Stereological counts were
obtained using a computer-assisted image analysis system
consisting of an Axiophot 2 photomicroscope (Carl Zeiss
Inc., Thornwood, NY, USA) equipped with a computer-
controlled motorized stage (Ludl Electronics, Hawthorne,
NY, USA), a Hitachi HV C20 video camera, and interfaced
with a StereoInvestigator system (MicroBrightField Inc., Will-
iston, VT, USA) with optical fractionator probe. We used a
counting frame of 40 × 40 mm, a 1 mm guard, a sampling
grid of 100 × 100 mm and a dissector height of 8 mm. For
Nissl counting, a cell was defined as a bright blue-stained
neuronal perikarya with a nucleolus. Nissl-positive counts
were restricted to Nissl+/TH+ neurons along with large
Nissl+ neurons with dopaminergic-like morphology, which
contain little or no TH immunostaining. Counts were per-
formed by investigators blinded to the genotype of each
animal.
Stereological measurements of immunoreactive areas
Area fraction analysis was performed as described previously
(43). Coronal brain sections (40 mm) from matched anatomic-
al regions for each mouse genotype (n ¼ 3 brains per geno-
type, 1 section per region) were selected for each antibody
(pSer129-a-synuclein, GFAP or Iba1). After immunostaining,
each section was first microscopically assessed at low magni-
fication (×5 objective) to identify regions with the highest
level of phospho-Ser129-a-synuclein, GFAP or Iba1 immu-
noreactivity. A StereoInvestigator system (MicroBrightField
Inc.) and a ×5 objective were used to mark the contours
encompassing the right and left SNpc, LCN, LVN and RF.
Immunoreactivity within each area (right and left sides) was
measured using a ×40 objective and the area-fraction fractio-
nator probe (sampling grid size: SNpc, 300 × 300 mm; LCN,
175 × 150 mm; LVN, 150 × 100 mm; RF, 200 × 100 mm).
At each sampling site, a counting grid (SNpc, 300 ×
300 mm; LCN, 175 × 150 mm; LVN, 150 × 100 mm; RF,
200 × 100 mm) was superimposed consisting of markers
equally spaced from one another at a distance of 15 mm.
Markers that co-localized with immunoreactivity were
labeled as positive, whereas remaining markers were labeled
as negative. The area fraction was calculated as the number
of positive markers divided by the total number of markers
superimposed on the counting frame. Stereological assess-
ments were performed by investigators blinded to the geno-
type of each animal.
In situ hybridization
Fresh-frozen coronal sections from A53T-a-Syn (7
months-old) or G2019S-LRRK2 (9 or 12 months-old) trans-
genic mice, and their age-matched non-transgenic littermate
controls were subjected to in situ hybridization as previously
described (24,44) using 33P-labeled oligonucleotide probes
complementary to mouse/human a-synuclein (nt 522–571;
NM_007308.2), mouse a-synuclein (nt 738–787; NM_
001042451.1), human LRRK2 (nt 4436–4483; NM_
198578.3), mouse LRRK2 (nt 6036–6085; NM_025730.2)
or mouse TH (nt 197–248; NM_009377.1). Messenger RNA
signals were revealed by exposure of slides to autoradiograph-
ic film or were dipped in photographic emulsion (NB2, Kodak)
for microscopy analysis.
Behavioral analysis
Behavioral analysis of A53T-a-Syn/LRRK2-KO mice and
their littermate controls at 6 months of age were conducted
as described previously (24,34). ‘Open-field test’:
novelty-induced locomotor activity in the open-field quadrant
was assessed over a 60 min period using a Cage Rack Flex-
Field Photobeam Activity System (San Diego Instruments,
San Diego, CA, USA) which provides horizontal and vertical
grids of 16 × 16 infrared beams. The total number of beam
breaks in both horizontal and vertical planes was recorded
during the test. Activity during the first 15 min period was
used for analysis. ‘Acoustic startle response’: for acoustic
startle, mice were assessed for the maximal amplitude of the
acoustic startle response in an SR-LAB Startle Reflex
system (San Diego Instruments). Mice were habituated by
5 min of background noise and then exposed to a series of
acoustic stimuli (40 ms duration) ranging from 75 to 120 dB,
including two 0 dB baseline measurements, occurring in a
pseudorandom order. The interval between each stimulus
was 15 s, and the series of stimuli were repeated six times.
The maximal amplitude of each motor response was deter-
mined. The average value of six repeats for the 120 dB stimu-
lus intensity was calculated and used for statistical analysis of
mouse genotypes.
Statistical analysis
Data were expressed as mean+SEM. Statistical analysis was
performed by one-way ANOVA with Newman–Keuls post
hoc test. A value of P, 0.05 was considered significant.
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